Thursday 21 July 2016 3:15 – 6:00 pm
MGSM Conference Centre
99 Talavera Road, Macquarie Park
3:15 – 3:30 pm Registration
3:30 – 4:15 pm David Grainger, Senior Director in the Global Public Policy group at Eli Lilly Patients are a virtue (the role of the patient in the PBAC/PBS process)
4:15 – 4:30 pm Andrew Moore and Matt Martin, Interact Technology
Demonstration and launch of our member-only app called APP-A
4:30 – 5:15 pm Michelle Gallaher, The Social Science Emerging role of social media in pharma – presentation on the emerging role of social media in clinical trials, expert/external stakeholder engagement.
5:15 – 6:00 pm Networking Drinks
David Grainger is the Senior Director in the Global Public Policy group at Eli Lilly & Company. In this role, he is responsible for developing and supporting the company’s external health care policy positions related to Health Technology Assessment (HTA). David also engages with governments and thought leaders in a range of markets on policy issues related to universal health coverage, formulary management, HTA, pricing and regulatory affairs.
David joined Lilly in 1980 and has had a range of roles in sales, marketing, health outcomes research and corporate affairs. Prior to joining the Global Public Policy group in July 2008, David was Director, Corporate Affairs & Health Outcomes in Lilly’s Australian affiliate. David was responsible for all health outcomes research, reimbursement dossier development & pricing functions as well as the corporate affairs functions of government relations, advocacy & communications.
Since February 2011 David has chaired the HTA Task Force for PhRMA International. In 2011-2012 he was a member of the Board of Directors of Health Technology Assessment International, a professional society dedicated to HTA. For 2013-2014 and 2014-2015, David was appointed an ex-offico member of the Board of HTAi to represent the industry sector. In 2015 David was elected as a full member of the Board of HTAi. He is a graduate of the University of Auckland with a BSc with majors in hematology and immuno-hematology. He has also studied management at the New Zealand Institute of Management and health economics at Monash University in Melbourne, Australia. David is the co-author of numerous publications on health economics and health outcomes research.
Michelle Gallaher (The Social Science) is the Co-Founder and Creative Director of a company called The Social Science, which provides consulting services on social media (http://thesocialscience.com.au/about-us/). She is connected with and supportive of the Australian biotechnology and pharmaceutical industries; and is the former Director of the BioMelbourne Network, a peak body for biotech and med-tech (http://biomelbourne.org/), and is on the board of Cancer Trials Australia.